IONS Ionis Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: IONS
Price (delayed)
$41.41
Market cap
$6.6B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.76
Enterprise value
$7.72B
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and
Highlights
The company's equity has surged by 140% YoY and by 33% QoQ
The net income has increased by 41% since the previous quarter and by 27% year-on-year
IONS's quick ratio has dropped by 70% since the previous quarter and by 62% year-on-year
Key stats
What are the main financial stats of IONS
Market
Valuations
Earnings
Shares outstanding
159.39M
Market cap
$6.6B
Enterprise value
$7.72B
Price to earnings (P/E)
N/A
Price to book (P/B)
10.43
Price to sales (P/S)
6.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.18
Revenue
$944.05M
Gross profit
$933.54M
Operating income
-$266.52M
Net income
-$268.22M
EBIT
-$183.19M
EBITDA
-$161.57M
Free cash flow
-$290M
Per share
Balance sheet
Liquidity
EPS
-$1.76
EPS diluted
-$1.84
Free cash flow per share
-$1.82
Book value per share
$3.97
Revenue per share
$5.93
TBVPS
$18.76
Total assets
$2.99B
Total liabilities
$2.35B
Debt
$1.42B
Equity
$631.72M
Working capital
$1.68B
Debt to equity
2.25
Current ratio
2.87
Quick ratio
2.61
Net debt/EBITDA
-6.95
Margins
Efficiency
Dividend
EBITDA margin
-17.1%
Gross margin
98.9%
Net margin
-28.4%
Operating margin
-28.2%
Return on assets
-9%
Return on equity
-45.5%
Return on invested capital
-5%
Return on capital employed
-8.8%
Return on sales
-19.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IONS stock price
How has the Ionis Pharmaceuticals stock price performed over time
Intraday
1.4%
1 week
-3.81%
1 month
-0.77%
1 year
-12.01%
YTD
18.45%
QTD
4.81%
Financial performance
How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$944.05M
Gross profit
$933.54M
Operating income
-$266.52M
Net income
-$268.22M
Gross margin
98.9%
Net margin
-28.4%
The operating margin has surged by 57% since the previous quarter and by 37% year-on-year
The company's net margin has surged by 56% QoQ and by 37% YoY
IONS's operating income is up by 44% since the previous quarter and by 27% year-on-year
The net income has increased by 41% since the previous quarter and by 27% year-on-year
Price vs fundamentals
How does IONS's price correlate with its fundamentals
Growth
What is Ionis Pharmaceuticals's growth rate over time
Valuation
What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
10.43
P/S
6.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.18
Ionis Pharmaceuticals's EPS has increased by 41% QoQ and by 30% YoY
The company's equity has surged by 140% YoY and by 33% QoQ
The stock's price to book (P/B) is 11% less than its 5-year quarterly average of 11.7 but 9% more than its last 4 quarters average of 9.6
IONS's revenue is up by 32% QoQ and by 16% YoY
The P/S is 12% less than the 5-year quarterly average of 7.9
Efficiency
How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has surged by 63% QoQ and by 40% YoY
IONS's return on equity has surged by 61% year-on-year and by 51% since the previous quarter
Ionis Pharmaceuticals's ROIC has increased by 49% from the previous quarter and by 32% YoY
IONS's return on assets is up by 43% since the previous quarter and by 30% year-on-year
Dividends
What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IONS.
Financial health
How did Ionis Pharmaceuticals financials performed over time
The total assets is 27% greater than the total liabilities
The current ratio has dropped by 70% since the previous quarter and by 62% year-on-year
IONS's quick ratio has dropped by 70% since the previous quarter and by 62% year-on-year
The company's debt is 125% higher than its equity
The company's equity has surged by 140% YoY and by 33% QoQ
Ionis Pharmaceuticals's debt to equity has plunged by 59% YoY and by 24% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.